In a letter sent to Sen. Orrin Hatch (R-Utah) last week, ASHP commended a legislative proposal that promotes notification and provides economic incentives to reduce drug shortages, but noted that one provision could result in the loss of patient access to needed care.
The draft bill would provide three economic incentives for manufacturers of sterile injectable products with four or fewer manufacturers:
In the letter, ASHP expressed concern with the 340B exemption and the potential impact it may have on safety net hospitals. The Society pointed to a report from the Office of the Assistant Secretary for Planning and Evaluation that does not identify federal health programs as causes of drug shortages. ASHP also noted that it has not identified a correlation between reimbursement rates and drug shortages.
Read ASHP’s letter to Sen. Hatch
Public Relations Division
Stay connected with ASHP through our social media tools.
What We Do
For the Press
Jobs at ASHP
AHFS Drug Information
Customer Service: 1-866-279-0681
8:00am - 6:00pm ET, Mon-Fri
American Society of Health-System Pharmacists. All rights reserved. 7272 Wisconsin Avenue, Bethesda, MD 20814